SCHEDULE: Farallon Capital Discloses Stake in Tango Therapeutics

Farallon Capital Management entities have reported beneficial ownership of over 7.8% of Tango Therapeutics' common stock, including shares underlying warrants.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Tango Therapeutics, Inc. common stock.
• Multiple entities and individuals associated with Farallon Capital Management are listed as reporting persons.
• The reporting persons collectively beneficially own 9,097,411 shares of common stock and 2,159,792 warrants.
• The warrants are exercisable into common stock, subject to a Beneficial Ownership Limitation of 9.99%.
• As of the filing date, the Beneficial Ownership Limitation does not restrict the exercise of these warrants.
• The total beneficial ownership, including shares underlying exercisable warrants, represents 7.8% of Tango Therapeutics' outstanding common stock.
• The filing date for this amendment is March 31, 2026, with signatures dated May 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on ownership changes and does not provide operational or financial performance details of the underlying company.

Positives

• Farallon Capital Management entities have taken a significant stake in Tango Therapeutics, potentially signaling confidence in the company's prospects.
• The reporting persons have the right to acquire a substantial number of additional shares through warrants, indicating a potential for increased ownership.
• The Beneficial Ownership Limitation does not currently restrict the exercise of these warrants, allowing for full potential ownership realization.

Negatives

• The filing does not contain financial performance data or operational updates for Tango Therapeutics, focusing solely on ownership.
• The significant stake held by a single investment firm could be perceived as a concentration of ownership, potentially impacting market dynamics.

Risks

• The Beneficial Ownership Limitation of 9.99% on warrants could restrict future exercise if the company's outstanding shares increase significantly.
• The concentration of ownership among Farallon Capital entities could lead to potential conflicts of interest or influence over corporate decisions.
• The filing does not provide insight into the specific investment strategy or rationale behind acquiring this stake, leaving the market to speculate.

Future Outlook

The filing does not contain forward-looking statements or guidance from Tango Therapeutics. The future outlook is primarily related to the potential exercise of warrants and the associated ownership levels.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by large investment firms like Farallon Capital in biotechnology companies like Tango Therapeutics often reflect a belief in the company's pipeline or technology, especially in the competitive biotech landscape.

Stakeholder Impact

• Shareholders may view the increased stake by a major investment firm positively, potentially indicating confidence in the company's future.
• The concentration of ownership could influence future corporate actions and strategic decisions, impacting all stakeholders.

Next Steps

• Monitoring of Tango Therapeutics' stock performance and any future disclosures from Farallon Capital Management.
• Observation of whether the warrants are exercised and the impact on outstanding share count and ownership percentages.

Key Dates

Recommendation

This filing is a Schedule 13G, which reports beneficial ownership and does not contain operational or financial performance data for Tango Therapeutics. While the acquisition of a significant stake by Farallon Capital may signal confidence, without further information on the company's performance or strategy, a 'hold' recommendation is prudent for seasoned investors.

Keywords

Tango Therapeutics, Schedule 13G, Farallon Capital Management, Beneficial Ownership, Warrants, SEC Filing, Investment, Stock Ownership